NCT04689035View on ClinicalTrials.gov

A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 27, 2020

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2023

Conditions
Safety IssuesTolerance
Interventions
DRUG

AVLX-144

Test drug

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

Clinical Research Services Turku / CRST Oy, Turku

Sponsors

Lead Sponsor

Avilex Pharma
All Listed Sponsors
lead

Avilex Pharma

INDUSTRY

NCT04689035 - A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144 | Biotech Hunter | Biotech Hunter